Sirtuin-1 and HIV-1: An overview

Current Drug Targets

Volumn 14, Issue 6, 2013, Pages 648-652

  Pinzone, Marilia Rita ^a   Cacopardo, Bruno ^a   Condorelli, Fabrizio ^b   Di Rosa, Michele ^a   Nunnari, Giuseppe ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Deacetylase activity; HDAC; HIV 1; Resveratrol; SIRT1; Sirtuin

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; NICOTINAMIDE; RESVERATROL; SIRTUIN 1; SYNAPTOTAGMIN I; TRANSACTIVATOR PROTEIN;

DEACETYLATION; ENERGY METABOLISM; FIBROSIS; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; REVIEW;

HIV INFECTIONS; HIV-1; HUMANS; SIRTUIN 1; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 84878532308     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314060005     Document Type: Review

References (67)

1. Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF. The multifactorial nature of HIV-1 latency. Trends Mol Med 2004; 10: 525-31.
2. Nunnari G, Otero M, Dornadula G, et al. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS 2002; 16: 39-45.
3. Nunnari G, Sullivan J, Xu Y, et al. HIV type 1 cervicovaginal reservoirs in the era of HAART. AIDS Res Hum Retroviruses 2005; 21: 714-18.
4. Dornadula G, Nunnari G, Vanella M, et al. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis 2001; 183: 1682-87.
5. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338: a3172.
6. Nunnari G, Berretta M, Pinzone MR, et al. Hepatocellular carcinoma in HIV positive patients. Eur Rev Med Pharmacol Sci 2012; 16: 1257-70.
7. Berretta M, Lleshi A, Cappellani A, et al. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr HIV Res 2010; 8: 218-22.
8. Zanet E, Berretta M, Di Benedetto F, et al. Pancreatic Cancer in HIV-Positive Patients: A Clinical Case-Control Study. Pancreas 2012; 41: 1331-35.
9. Pinzone MR, Fiorica F, Di Rosa M, et al. Non-AIDS-defining cancers among HIV-infected people. Eur Rev Med Pharmacol Sci 2012; 16: 1377-88.
10. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005; 435: 108-14.
11. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1: 1284-90.
12. Pinzone MR, Di Rosa M, Cacopardo B, Nunnari G. HIV RNA Suppression and Immune Restoration: Can We Do Better? Clin Develop Immunol 2012, 515962.
13. Nunnari G, Argyris E, Fang J, Mehlman KE, Pomerantz RJ, Daniel R. Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines. Virology 2005; 335: 177-84.
14. Smith JA, Nunnari G, Preuss M, Pomerantz RJ, Daniel R. Pentoxifylline suppresses transduction by HIV-1-based vectors. Intervirology 2007; 50: 377-86.
15. Chen K, Huang J, Zhang C, et al. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J Virol 2006; 80: 7645-57.
16. Otero M, Nunnari G, Leto D, et al. Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Res Hum Retroviruses 2003; 19: 1097-103.
17. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326: 711-13.
18. Fortin JF, Barat C, Beausejour Y, Barbeau B, Tremblay MJ. Hyper-responsiveness to stimulation of human immunodeficiency virus-infected CD4+ T cells requires Nef and Tat virus gene products and results from higher NFAT, NF-kappaB, and AP-1 induction. J Biol Chem 2004; 279: 39520-31.
19. Ott M, Emiliani S, Van Lint C, et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997; 275: 1481-85.
20. Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al. HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J 1995; 14: 546-54.
21. Nunnari G, Smith JA, Daniel R. HIV-1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier? J Exp Clin Cancer Res 2008; 27: 3.
22. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
23. Kinter AL, Poli G, Fox L, Hardy E, Fauci AS. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995; 154: 2448-59.
24. Kreisberg JF, Yonemoto W, Greene WC. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J Exp Med 2006; 203: 865-70.
25. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NFkappaB action regulated by reversible acetylation. Science 2001; 293: 1653-57.
26. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NFkappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23: 2369-80.
27. Kao SY, Calman AF, Luciw PA, Peterlin BM. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 1987; 330: 489-93.
28. Feng S, Holland EC. HIV-1 tat trans-activation requires the loop sequence within tar. Nature 1988; 334: 165-67.
29. Rosen CA, Sodroski JG, Haseltine WA. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell 1985; 41: 813-23.
30. Zhu Y, Pe'ery T, Peng J, et al. Transcription elongation factor PTEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 1997; 11: 2622-32.
31. Dorr A, Kiermer V, Pedal A, et al. Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain. EMBO J 2002; 21: 2715-23.
32. Pagans S, Pedal A, North BJ, et al. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 2005; 3: e41.
33. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012; 13: 225-38.
34. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404: 1-13.
35. Borra MT, O'Neill FJ, Jackson MD, et al. Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases, J Biol Chem 2002; 277: 12632-41.
36. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and human SIRT1. J Biol Chem 2002; 277: 45099-107.
37. Schmidt MT, Smith BC, Jackson MD, Denu JM. Coenzyme specificity of Sir2 protein deacetylases, J Biol Chem 2004; 279: 40122-29.
38. Kustatscher G, Hothorn M, Pugieux C, Scheffzek K, Ladurner AG. Splicing regulates NAD metabolite binding to histone macroH2A. Nat Struct Mol Biol 2005; 12: 624-25.
39. Du J, Jiang H, Lin H. Investigating the ADP-ribosyltransferase activity of sirtuins with NAD analogues and 32P NAD. Biochemistry 2009; 48: 2878-90.
40. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005; 16: 4623-35.
41. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 2004; 16: 93-105.
42. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 2001; 107: 137-48.
43. Vaziri H, Dessain SK, Eaton EN, et al. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107: 149-59.
44. Schemies J, Sippl W, Jung M. Histone deacetylase inhibitors that target tubulin. Cancer Lett 2009; 280: 222-32.
45. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002; 32: 606-13.
46. Jiang JC, Jaruga E, Repnevskaya MV, Jazwinski SM. An intervention resembling caloric restriction prolongs life span and retards aging in yeast. FASEB J 2000; 14: 2135-37.
47. Lakowski B, Hekimi S. The genetics of caloric restriction in Caenorhabditis elegans. Proc Natl Acad Sci 1998; 95: 13091-96.
48. Mair W, Goymer P, Pletcher SD, Partridge L. Demography of dietary restriction and death in Drosophila. Science 2003; 301: 1731-33.
49. Herranz D, Muñoz-Martin M, Cañamero M, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 2010; 1: 3.
50. Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-63.
51. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-15.
52. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-κBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23: 2369-80.
53. Zhang J, Lee SM, Shannon S, et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 2009; 119: 3048-58.
54. Sequeira J, Boily G, Bazinet S, et al. sirt1-null mice develop an autoimmune-like condition. Exp Cell Res 2008; 314: 3069-74.
55. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 17: 7861-70.
56. Yoshizaki T, Schenk S, Imamura T, et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab 2010; 298: E419-28.
57. Legutko A, Marichal T, Fievez L, et al. Sirtuin 1 promotes Th2 responses and airway allergy by repressing peroxisome proliferator-activated receptor-{gamma} activity in dendritic cells. J Immunol 2011; 187: 4517-29.
58. Kim SR, Lee KS, Park SJ, et al. Involvement of sirtuin 1 in airway inflammation and hyperresponsiveness of allergic airway disease. J Allergy Clin Immunol 2010; 125: 449-60.
59. Li J, Qu X, Ricardo SD, Bertram JF, Nikolic-Paterson DJ. Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am J Pathol 2010; 177: 1065-71.
60. Mbonye U, Karn J. Control of HIV Latency by Epigenetic and Non-Epigenetic Mechanisms. Curr HIV Res 2011; 9: 554-67.
61. Zhang HS, Zhou Y, Wu MR, Zhou HS, Xu F. Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD+-dependent SIRT1 activity. Life Sci 2009; 85: 484-89.
62. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-22.
63. Zhang HS, Sang WW, Wang YO, Liu W. Nicotinamide phosphoribosyltransferase/ sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation. J Cell Biochem 2010; 110: 1464-70.
64. Park SJ, Ahmad F, Philp A, et al. Resveratrol Ameliorates Aging- Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases. Cell 2012; 148(3): 421-33.
65. Kwon HS, Brent MM, Getachew R, et al. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 2008; 3: 158-67.
66. Thakur BK, Chandra A, Dittrich T, Welte K, Chandra P. Inhibition of SIRT1 by HIV-1 viral protein Tat results in activation of p53 pathway. Biochem Biophys Res Commun 2012; 424: 245-50.
67. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death- a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-32.